Mutua Madrileña funds IDIBELL and ICO project to improve diagnosis of Lynch syndrome

June 25, 2013, IDIBELL-Bellvitge Biomedical Research Institute

The Fundación Mutua Madrileña, in its 10th Call for Aids to Research, has selected a project to improve the diagnosis of Lynch syndrome led by researcher Marta Pineda, from the Hereditary Cancer research group of the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO). The aid is provided with 33,000 euros and has a duration of two years.

Hereditary predisposition to cancer

Lynch syndrome is a to cancer caused by in . Families with Lynch syndrome have a higher risk of developing several types of cancer, especially of colon and endometrium.

Mutational analysis of repair genes often identifies genetic variants of unknown significance, of which we cannot predict its biological significance and clinical consequences. Identification of a variant of unknown significance is an important limitation for proper risk assessment of . Such variants represent a 30% of the alterations detected in mutational analysis repair genes.

The aim of the project funded by the Fundación Mutua Madrileña is to study the pathogenicity of the variants identified in repair genes and MSH6.

The funding of this project will imply the incorporation of the functional study of these variants in the routine of the Molecular Diagnostic Unit of ICO and a significant improvement in molecular diagnostics of Lynch syndrome.

The determination of the pathogenicity of a variant is essential to help Genetic Counselling Units in doing family counselling and allows predictive studies of risk and prevention measures and an adequate monitoring.

Improvements in diagnosis

On the other hand, together with the announcement of this aid, the researchers of the hereditary cancer group at IDIBELL and ICO, under the direction of Gabriel Capellá have published in the Journal of Medical Genetics a study identifying the first PMS2 mutations in Spain. The study also involved the Institute of Medicine and Molecular Oncology of Asturias (IMOMA) and the University of Frankfurt.

Mutational analysis of PMS2 is particularly complex since there are multiple pseudogenes (sequences similar to that of our genes but with no protein expression capacity) that hinder it. The IMOMA uses a special methodology that avoids pseudogenes and identifies mutations in PMS2 in a more reliable way. Subsequently, the functional study of variants of unknown significance made by ICO and the University of Frankfurt has allowed classifying the variants identified in the PMS2 gene.

This exhaustive strategy of molecular study in the genetic analysis of PMS2 gene has allowed the identification of mutations responsible for the syndrome in 69% of the analyzed patients.

Explore further: Three mutations at BRCA1 gene responsible for breast and ovarian hereditary cancer

More information: Journal of Medical Genetics. doi: 10.1136/jmedgenet-2012-101511

Related Stories

Three mutations at BRCA1 gene responsible for breast and ovarian hereditary cancer

April 18, 2013
Researchers of the hereditary cancer research group at the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) conducted a functional and structural study of seven missense variants ...

Spanish researchers develop new method to diagnose hereditary breast and ovarian cancer

January 16, 2013
Researchers of the Catalan Institute of Oncology (ICO) at the Bellvitge Biomedical Research Institute (IDIBELL) have developed and validated a new method to diagnose hereditary breast and ovarian cancer syndrome based on ...

Genetic test results for Lynch syndrome improved with new computer program

November 1, 2012
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance." This can be a problem, as people with ...

Study identifies genetic mutations associated with cancer risk for hereditary cancer syndrome

June 5, 2011
(Medical Xpress) -- Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified ...

A new molecular mechanism in breast cancer development

November 15, 2011
About 10% of breast cancers are due to mutations in genes called BRCA1 and BRCA2. However, the molecular mechanism by which alteration of these genes greatly increases the risk of cancer is not fully understood. In a new ...

Health of entire families at risk through under-use of genetic testing

June 7, 2013
A new study of the use of genetic testing for cancer-causing mutations in affected families in France has found that its take-up is very low. Professor Pascal Pujol, Head of the Cancer Genetics Department, Montpellier University ...

Recommended for you

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma

January 17, 2018
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at ...

Dulling cancer therapy's double-edged sword

January 17, 2018
Researchers have discovered that killing cancer cells can actually have the unintended effect of fueling the proliferation of residual, living cancer cells, ultimately leading to aggressive tumor progression.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.